Introduction:The Shengxian decoction(SXT),a Chinese herbal medication used to treat heart failure,is composed of Astragali Radix,Anemarrhenae Rhizoma,Bupleuri Radix,Cimicifuage Rhizoma,and Platycodonis Radix.Knowledge...Introduction:The Shengxian decoction(SXT),a Chinese herbal medication used to treat heart failure,is composed of Astragali Radix,Anemarrhenae Rhizoma,Bupleuri Radix,Cimicifuage Rhizoma,and Platycodonis Radix.Knowledge of the excretion of the active compounds in this herbal medication is vital for investigating the underlying mechanisms behind its compatibility.However,this remains unclear.Methods:Liquid chromatography coupled with mass spectrometry was performed in both positive and negative modes to assay 18 constituents of SXT from rat urinary,fecal,and biliary samples.Results:The methodology was validated and showed good linearity(r≥0.9),precision,stability,repeatability,and recovery.The relative standard deviations and relative errors for the precision and accuracy did not exceed 15%.The recoveries of all the compounds ranged from 77.37%to 114.82%,and the matrix effect was between 82.53%and 105.71%.The results suggested that,when combined with Platycodonis Radix,the levels of 14 constituents from the four herbs were reduced in the urine,while the levels of six constituents were reduced in the feces.Conclusions:The comparative excretion results indicated that Platycodonis Radix reduced the excretion of compounds in SXT,demonstrating the compatibility mechanism and holistic properties of these compounds,favoring the pharmacological effects of SXT.展开更多
目的:探讨益气升陷活血方及其拆方对心梗后心衰低血压大鼠心肌Ⅰ、Ⅲ型胶原的影响。方法:采用大鼠心脏左冠状动脉结扎术,建立心衰模型,将LVEF值≤50%、尾动脉收缩压≤90 mm Hg的大鼠随机分为4组,即心衰低血压组、益气升陷活血方组、益...目的:探讨益气升陷活血方及其拆方对心梗后心衰低血压大鼠心肌Ⅰ、Ⅲ型胶原的影响。方法:采用大鼠心脏左冠状动脉结扎术,建立心衰模型,将LVEF值≤50%、尾动脉收缩压≤90 mm Hg的大鼠随机分为4组,即心衰低血压组、益气升陷活血方组、益气升陷组、活血化瘀组,灌胃干预8周。用免疫组化及RT-PCR检测心肌Ⅰ、Ⅲ型胶原,并实时定量PCR检测心肌Ⅰ、Ⅲ型胶原m RNA的含量。结果:与心衰低血压组比较,所有治疗组心肌Ⅰ、Ⅲ型胶原含量及m RNA的含量均降低(P<0.05);与活血化瘀治疗组比较,益气升陷组、全方治疗组,心肌Ⅰ、Ⅲ型胶原m RNA的含量均降低,全方治疗组更显著(P<0.05)。结论:全方治疗组、益气升陷组、活血化瘀组能减轻心梗后心衰大鼠心肌纤维化的程度,减少心肌Ⅰ、Ⅲ型胶原的含量,其中全方治疗组较益气升陷治疗组、活血化瘀治疗组的改善作用明显,益气升陷组次之。展开更多
基金supported by National Key R&D Program of China(2022YFC3501700)National Natural Science Foundation of China(82274059)+1 种基金Science and Technology Commission of Shanghai Municipality(22S21901900)Organizational Key Research and Development Program of Shanghai University of Traditional Chinese Medicine(2023YZZ02)。
文摘Introduction:The Shengxian decoction(SXT),a Chinese herbal medication used to treat heart failure,is composed of Astragali Radix,Anemarrhenae Rhizoma,Bupleuri Radix,Cimicifuage Rhizoma,and Platycodonis Radix.Knowledge of the excretion of the active compounds in this herbal medication is vital for investigating the underlying mechanisms behind its compatibility.However,this remains unclear.Methods:Liquid chromatography coupled with mass spectrometry was performed in both positive and negative modes to assay 18 constituents of SXT from rat urinary,fecal,and biliary samples.Results:The methodology was validated and showed good linearity(r≥0.9),precision,stability,repeatability,and recovery.The relative standard deviations and relative errors for the precision and accuracy did not exceed 15%.The recoveries of all the compounds ranged from 77.37%to 114.82%,and the matrix effect was between 82.53%and 105.71%.The results suggested that,when combined with Platycodonis Radix,the levels of 14 constituents from the four herbs were reduced in the urine,while the levels of six constituents were reduced in the feces.Conclusions:The comparative excretion results indicated that Platycodonis Radix reduced the excretion of compounds in SXT,demonstrating the compatibility mechanism and holistic properties of these compounds,favoring the pharmacological effects of SXT.
